Iovance Biotherapeutics Stock Price - IOVA

Best deals to access real time data!
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
CHART Trader
Monthly Subscription
for only
$30.66
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
After Hours
Last Trade
Last $ 25.10 ▼ -0.07 (-0.28%)
Company Name Stock Ticker Symbol Market Type
Iovance Biotherapeutics Inc IOVA NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.04 0.16% 25.17 25.72 24.70 25.01 25.13 23:59:46
Bid Price Ask Price Spread Spread % News
16.14 27.57 11.43 41.46% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
8,341 753,372 $ 25.07 $ 18,888,452 1,282,880 7.26 - 26.59
Last Trade Time Type Quantity Stock Price Currency
17:49:14 formt 199 $ 25.10 USD

Iovance Biotherapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.18B 126.19M $ -123.58M -1.27 - 105.17M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 16.70%

more financials information »

Iovance Biotherapeutics News

Loading Messages....

Latest IOVA Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical IOVA Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week24.6626.2523.9825.211,288,3120.512.07%
1 Month22.4326.2520.6023.571,241,5662.7412.22%
3 Months20.7226.2517.6721.241,283,3374.4521.48%
6 Months18.9426.5917.6721.791,314,6606.2332.89%
1 Year10.0126.597.2617.031,363,84615.16151.45%
3 Years7.0026.594.4514.30949,46418.17259.57%
5 Years8.5726.594.2413.09749,58916.60193.7%

Iovance Biotherapeutics Description

Iovance Biotherapeutics Inc operates in the healthcare sector based in the United States. It is a pharmaceutical manufacturer attending to serious diseases such as cancer. The Company's lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The TIL therapy involves growing a patient's special culture conditions outside the patient's body, or ex vivo, and then infusing the T cells back into the patient.


Your Recent History
NASDAQ
IOVA
Iovance Bi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.